## **Declaration for Patent Application**

As a below named inventor, I hereby declare that:

Direct Telephone Calls to:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled **HIV-Peptide-Carrier-Conjugates**, the specification of which is attached hereto unless the following box is checked:

$\boxtimes$	was filed on March	<u>25, 2004;</u>			
	as PCT Internationa	al Application Number <u>I</u>	PCT/EP2004/003163; and		
	was amended on	<u>herewith</u> (if applica	ble).		
			tand the contents of the a any amendment referred to		tified
37 C.l becam	F.R. § 1.56, including ne available between	g for continuation-in-pa	at is material to patentabilert applications, material interprise application and the application.	formation w	vhich
foreig 365(a the U box, a PCT	n application(s) for of any PCT internat nited States of Amer any foreign application	patent, inventor's or tional application, which ica, listed below, and hon for patent, inventor's	J.S.C. § 119(a)-(d) or (f) or plant breeder's rights cent designated at least one contains are also identified below, as or plant breeder's rights the before that of the application.	rtificate(s), ountry other by checking certificate(s	or § than g the s), or
Prior	Foreign Applications	(s):			iority imed
	<b>U</b> 11	. ,		☐ Yes	□ No
(Appl	ication No.)	(Country)	(Day/Month/Year Filed)	100	
		,		☐ Yes	□ No
(Appl	ication No.)	(Country)	(Day/Month/Year Filed)		
Send	Correspondence to: STI	Customer No. ERNE, KESSLER, GOLDST 1100 New York Av Washington, D.C.	TEIN & FOX P.L.L.C. venue, N.W.		

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

T 11		
Full name of first Inventor:	Martin F. BACHMANN	
Signature of first	00	
Inventor:	11.70	Date: 31.08.2005
mventor.		Date: 37.00. 200
Residence:	Seuzach, SWITZERLAND	
Citizenship:	Switzerland	
Mailing Address:	Goldackerweg 8 Seuzach, SWITZERLAND CH-8472	
Full name of second Inventor:	Adrian HUBER	
Signature of second		
Inventor:	Adm An	31.08.2005
D ::	Zu : 1 GWWZEDI AND	
Residence:	Zürich, SWITZERLAND	·
Citizenship:	Switzerland	
Mailing Address:	Eschergutweg 5	
ividining radiress.	Zürich, SWITZERLAND CH-8049	
Full name of third Inventor:	Vania MANOLOVA	
Signature of third	sarl	
Inventor:		Date: 31.08, 2005
	A /	2 2 (120, 230)
Residence:	Zürich/SWITZERLAND	
Citizenship:	Bulgaria	
N. C. 11	Pestalozzistrasse 41	, ,
Mailing Address:	Zurich, SWITZERLAND CH-8032	

Full name of fourth Inventor: Signature of fourth	Edwin MEIJERINK	- 24.00 200
Inventor: Residence:	Zürich, SWITZERLAND	Date: 31.08.2005
Citizenship:	The Netherlands	
Mailing Address:	Rebbergstrasse 50 Zurich, SWITZERLAND CH-8049	
Full name of fifth		

Full name of fifth Inventor:	Karl G. PROBA	
Signature of fifth Inventor:	Lugh folk	Date: 31.08, 2005
Residence:	Zürich, SWITZERLAND	
Citizenship:	Germany	
Mailing Address:	Tramstrasse 95 Zürich, SWITZERLAND CH-8050	

Full name of sixth Inventor:	Alain TISSOT	
Signature of sixth Inventor:	Asso	Date: 31.08. 2005
Residence:	Zürich, SWITZERLAND	
Citizenship:	Switzerland	
Mailing Address:	Segantinistrasse 35 Zürich, SWITZERLAND CH-8049	·

435492.1

## DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

## **ASSIGNMENT**

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Martin F. BACHMANN, (2) Adrian HUBER, (3) Vania MANOLOVA, (4) Edwin MEIJERINK, (5) Karl G. PROBA and (6) Alain TISSOT, hereby sell and assign to Cytos Biotechnology AG, a corporation formed under the laws of Switzerland, whose mailing address is Wagistrasse 25, CH-8952 Zürich-Schlieren, SWITZERLAND (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention known as HIV-Peptide-Carrier-Conjugates for which application(s) for patent in the United States of America was filed as International Application PCT/EP2004/003163, international filing date March 25, 2004, (designating the United States) in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Donald J. Featherstone, Esq., Registration No. 33,876; Robert C. Millonig, Esq., Registration No. 34,395; Michael V. Messinger, Esq., Registration No. 37,575; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick E. Garrett, Esq., Registration No. 39,987; Jeffrey Helvey, Registration No. 44,757; Heidi L. Kraus, Registration No. 43,730; Eldora Ellison, Registration No. 39,967; Thomas C. Fiala, Registration No. 43,610; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 31.08.2005	Signature of Inventor:	NRC
Date: 31.08.2005	Signature of Inventor:	(1) Martin F. BACHMANN (2) Adrian HUBER
Date: 31.08 2005	Signature of Inventor:	(3) Vania MANOLOVA
Date: 31.08. 2005	Signature of Inventor:	(4) Edwin MEIJERINK
Date: 31.08.2005	Signature of Inventor:	(5) Karl G. PROBA
Date: 31.08, 2005	Signature of Inventor:	(6) Alain TISSOT

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

435507.1

## POWER OF ATTORNEY FROM ASSIGNEE

Cytos Biotechnology AG, a corporation of Switzerland, having a principal place of business at Wagistrasse 25, Zurich-Schlieren, SWITZERLAND CH-8952, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on (1) 00 31/05 (2) 00/31/05 (3) 00/31/05 (4) 00/31/05 (5) 00/31/05 and (6) 00/31/05 of an invention known as HIV-Peptide-Carrier-Conjugates that is disclosed and claimed in a patent application of the same title by the inventors (1) Martin F. BACHMANN, (2) Adrian HUBER, (3) Vania MANOLOVA, (4) Edwin MEIJERINK, (5) Karl G. PROBA and (6) Alain TISSOT (said application filed on March 25, 2004 at the International Bureau of the World Intellectual Property Organization as PCT International Application No. PCT/EP2004/003163).

For the purpose of PAIR, the Customer Number is **26111**.

The Assignee hereby appoints the patent attorneys and agents associated with CUSTOMER NUMBER 26111 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith. The Assignee hereby grants said patent attorneys and agents associated with Customer Number 26111 the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

Customer Number 26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Cytos Biotechnology AG
SIGNATURE: \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
BY: Dr. Martin F. Bachmann
TITLE: CSO
DATE: August 31, 2005
FOR: Cytos Biotechnology AG
SIGNATURE:
BY: Dr. Martin Sperrle
TITLE: Director IP&Legal Affairs
DATE: August 31, 2005

435513.1

PTO/SB/96 (09-04)
Approved for use through 07/31/2006. 0MB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)			
Applicant/Patent Owner: Bachmann et al.			
Application No./Patent No.: PCT/EP2004/003163 Filed/Issue Date: Int'l Filing Date March 25, 2004			
Entitled: HIV-Peptide-Carrier-Conjugates			
Cytos Biotechnology AG , a Corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)			
states that it is: 1. $X$ the assignee of the entire right, title, and interest; or			
2. an assignee of less than the entire right, title and interest.  The extent (by percentage) of its ownership interest is%			
in the patent application/patent identified above by virtue of either:			
A\ \text{\text{\$\text{\$X\$}}} \ An assignment from the inventor(s) of the patent application/patent Identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.  OR			
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:			
From:     To:     The document was recorded in the United States Patent and Trademark Office at			
Reel, Frame, or for which a copy thereof is attached.			
2. From: To:			
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.			
3. From:			
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supplemental sheet.			
X Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]			
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.  August 31, 2005			
Signature Date  Dr. Martin F. Bachmann ; Dr. Martin Sperrle +41(44)7334747			
Printed or Typed Name Telephone Number			
CSO ; Director IP&Legal Affairs			
Title			

This collection of Information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.